The challenges associated with the dynamic expression of PD-L1 in tumors and its expression beyond the tumor necessitate further development of small molecules or antibody fragments and their labeling with shorter-lived radionuclides (43, 44), such as fluorine-18, for clinical applications. This evidence concerns the gene CD274 and neoplasm.